9-苄基-6-氯-2-异丙基-9H-嘌呤 | 1026640-83-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 9-苄基-6-氯-2-异丙基-9H-嘌呤
• 英文名称: 9-Benzyl-6-chloro-2-propan-2-ylpurine
• CAS: 1026640-83-4
• 化学式: C₁₅H₁₅ClN₄
• 分子量: 286.764
• InChiKey: JNJAEQUGKUYFAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-苄基-6-氯-2-异丙基-9H-嘌呤 在 氨 、 溴 、 sodium acetate 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 14.0h， 生成 9-benzyl-8-bromo-2-propan-2-ylpurin-6-amine
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects

  摘要：

  Recently we reported the adenine derivatives (2-4) as new interferon (IFN) inducers. In the present study, we conducted a detailed structure and activity relationship study of 4 and its related derivatives on IFN inducing activity. From this study, we found that compound 4 exhibited the most potent IFN inducing activity in vitro with a minimum effective concentration of 0.01 muM, and 4 also showed strong IFN-inducing activity at doses of more than 0.3 mg/kg by oral administration in mice. This potency was 10-fold stronger than that of Imiquimod. Moreover, 4 did not cause emesis in ferrets even at doses as high as 10 mg/kg, whereas. 80% of animals, were emetic when orally administered with the same dose of Imiquimod. These results indicate that compound 4 is superior to Imiquimod with respect to efficacy and safety. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00369-9
• 作为产物：
  描述：

  9-benzyl-2-propan-2-yl-1H-purin-6-one 在 三氯氧磷 作用下， 反应 3.0h， 生成 9-苄基-6-氯-2-异丙基-9H-嘌呤
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects

  摘要：

  Recently we reported the adenine derivatives (2-4) as new interferon (IFN) inducers. In the present study, we conducted a detailed structure and activity relationship study of 4 and its related derivatives on IFN inducing activity. From this study, we found that compound 4 exhibited the most potent IFN inducing activity in vitro with a minimum effective concentration of 0.01 muM, and 4 also showed strong IFN-inducing activity at doses of more than 0.3 mg/kg by oral administration in mice. This potency was 10-fold stronger than that of Imiquimod. Moreover, 4 did not cause emesis in ferrets even at doses as high as 10 mg/kg, whereas. 80% of animals, were emetic when orally administered with the same dose of Imiquimod. These results indicate that compound 4 is superior to Imiquimod with respect to efficacy and safety. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00369-9

文献信息

• Design, synthesis and structure–activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors
  作者：Pierre Raboisson、Claire Lugnier、Christian Muller、Jean-Marie Reimund、Dominique Schultz、Guillaume Pinna、Alain Le Bec、Hélène Basaran、Laurent Desaubry、François Gaudiot、Mohamed Seloum、Jean-Jacques Bourguignon

  DOI：10.1016/s0223-5234(02)01446-0

  日期：2003.2

  Adenine derivatives substituted in position 9 have been demonstrated to have potent cyclic nucleotide phosphodiesterase (PDE) inhibition properties with high selectivity toward PDE-4. Starting from our initial lead compound 9-(2-fluorobenzyl)-N(6)-methyl-2-trifluoromethyladenine (4, NCS613), we designed and synthesized a new series of 9-substituted derivatives for developing structure-activity relationship

  已经证明在9位取代的腺嘌呤衍生物具有有效的环核苷酸磷酸二酯酶（PDE）抑制特性，并且对PDE-4具有高选择性。从我们最初的先导化合物9-（2-氟苄基）-N（6）-甲基-2-三氟甲基腺嘌呤（4，NCS613）开始，我们设计并合成了一系列新的9-取代衍生物，用于开展结构-活性关系研究。这一系列新的衍生物显示出更高的效价和更好的选择性。在腺嘌呤环的三个不同位置上并行完成结构修饰，并得到以下观察结果：（i）引入亲脂性取代基（如三氟甲基），C-2位的正丙基或碘对于PDE-4抑制活性和对其他同工酶的选择性都有利；（ii）用2-甲氧基取代基对N9苄基进行官能化，导致活性更高的化合物；（iii）用其他氨基取代N（6）-甲基氨基部分对活性是有害的。在所有制备的衍生物中，9-（2-甲氧基苄基）-N（6）-甲基-2-三氟甲基腺嘌呤（9r），9-（2-甲氧基苄基）-N（6）-甲基-2-n-丙基腺嘌呤（9s） ），